AstraZeneca is selling off European commercial rights to its high blood pressure drug Atacand to German biotech Cheplapharm, securing $200 million for “company’s new wave of medicines”.

AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as it continues to slim down and invest in its pipeline.